BioScrip, Inc. (BIOS)
(Delayed Data from NSDQ)
$1.98 USD
+0.05 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.98 USD
+0.05 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.
Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
by Zacks Equity Research
Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
by Zacks Equity Research
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.
Why Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report?
by Zacks Equity Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip
by Zacks Equity Research
On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.
BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.
Why Is BioScrip (BIOS) Up 18.5% Since the Last Earnings Report?
by Zacks Equity Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook
by Zacks Equity Research
Bioscrip, Inc.'s (BIOS) shares witnessed a 2.2% fall in yesterday's trading session, closing at $1.78.
BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $5.2 million or loss of 6 cents per share in the fourth quarter of 2016, much narrower than the year-ago net loss of $16.9 million or loss of 28 cents.